Problem

Radiology demand is growing faster than the available radiologist workforce, creating longer waits for reads that guide urgent clinical decisions. Abdomen-pelvis CT is a particularly large and consequential workload, with more than 20 million U.S. exams annually. The core pain is that a critical finding can sit behind routine studies in a crowded worklist, delaying treatment and increasing the risk that urgent disease is not acted on quickly.

The killer use case is emergency and backlog triage: identifying suspected acute conditions such as small-bowel obstruction, free air, pancreatitis, or an abdominal aortic aneurysm and moving those studies to a radiologist sooner. Rather than asking clinicians to manage separate AI alerts for isolated diseases, a2z targets the broader operational problem of prioritizing the entire abdomen-pelvis CT queue.

Product / Service

a2z-Unified-Triage is an FDA-cleared radiological computer-aided triage and notification system for abdomen-pelvis CT. Its single model analyzes the whole scan in one pass for seven urgent findings—small-bowel obstruction, acute cholecystitis, acute pancreatitis, acute diverticulitis, hydronephrosis, free air, and unruptured abdominal aortic aneurysm—and flags suspected cases so they are moved to the top of the worklist. The product is offered for integration into U.S. practices' and health systems' existing workflows, with a2z also offering a review of historical scans before deployment.

The intended benefit is faster access to critical studies without requiring seven separate integrations. The system was validated across 12 clinical sites and a 675-case test cohort, with all seven findings meeting acceptance criteria. Separately, the company's prospective abdomen-pelvis study of AI-assisted preliminary report drafting reported a 17.8% reduction in reporting time, a 14.8% increase in radiologist confidence, and a 22.4% reduction in mental demand, suggesting a broader product direction beyond triage.

Market

a2z competes in clinical radiology AI, specifically FDA-cleared computer-aided triage and worklist-prioritization software for medical imaging. Its differentiation is breadth: a2z says existing solutions commonly address one condition at a time, while it is building toward comprehensive interpretation of a study. The clearest named competitor in the evidence is Aidoc, which also markets FDA-cleared comprehensive abdomen CT triage; a2z additionally competes with the wider set of single-condition radiology AI tools.

The company is an early-stage commercial entrant rather than a scaled incumbent. Founded in 2024, it raised a $4.5 million seed round co-led by Khosla Ventures and SeaX Ventures in December 2025, after receiving FDA clearance and presenting at RSNA 2025. The funding was earmarked for health-system partnerships, product development, and commercial rollout in 2026, and the product is described as available for clinical deployment. The gathered evidence does not disclose revenue or named customer deployments, so its demonstrated traction is regulatory clearance, multi-site validation, investor backing, and movement toward commercialization—not yet publicly documented commercial scale.